Medichems, a R&D based company, specializes in producing chemical analyzers for Urea Breath Test for diagnosis of Helicobacter pylori infection.
H. pylori infection has a world-wide distribution, but much more common in developing countries. In developing countries, the prevalence of infection increases rapidly during childhood and adulthood when it is usually as high as 80~90%. In contrast, in developed countries about 20% of individuals over the age of 40 years and 50% of those over the age of 60 years are infected.
H. pylori, a bacterium, is a principal cause of peptic ulcer, non-ulcer dyspepsia and chronic gastritis.
The Urea Breath Test is newly considered more accurate and simpler method than commonly used tests by utilizing endoscopic biopsy owing to its proven sensitivity and specificity, its ability to detect active H. pylori infection, and its non-invasive character.
HeliView, the company?s main product, is the most advanced medical equipment to detect H. pylori. It is basically designed to provide the most reliable system functions to fit customers? needs for highly sensitive and accurate test results.
HeliView also can be applied to other Breath Tests for diagnosis of liver function disease, fat metabolism, etc. In addition to the development on chemical analyzers, the company has the on-going project on development of new formulation of Diagnostic Test Kit for Helicobacter pylori infection in Human.
This project will enable the company to be more competitive as a total solution provider in this business. Based on these sustained core competencies, Medichems will become a leader of the UBT business in the near future.